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Abstract
Purpose PET/CT is now integral to the staging pathway for potentially curable esophageal cancer (EC), primarily to identify
distant metastases undetected by computed tomography. The aim of this study was to analyze the effect of PET/CT introduction
on survival and assess patterns of recurrence after esophagectomy.
Methods A longitudinal cohort of EC patients staged between 1998 and 2016 were considered for inclusion. After co-variate
adjustment using propensity scoring, a cohort of 496 patients (273 pre-PET/CT and 223 post-PET/CT) who underwent esoph-
agectomy [median age 63 years (31–80), 395 males, 425 adenocarcinomas, 71 squamous cell carcinomas, 325 neoadjuvant
therapy] were included. The primary outcome measure was overall survival (OS) based on intention to treat.
Results Three-year OS pre-PET/CTwas 42.5% compared with 57.8% post-PET/CT (Chi2 6.571, df 1, p = 0.004). On multivar-
iable analysis, pT stage (HR 1.496 [95% CI 1.28–1.75], p < 0.0001), pN stage (HR 1.114 [95% CI 1.04–1.19], p = 0.001) and
PET/CT staging (HR 0.688 [95% CI 0.53–0.89] p = 0.004) were independently associated with OS. Recurrent cancer was
observed in 125 patients (51.4%) pre-PET/CT, compared with 74 patients post-PET/CT (37.8%, p = 0.004), and was less likely
to be distant recurrence after PET/CT introduction (39.5 vs. 27.0%, p = 0.006).
Conclusions Enhanced PET/CT staging is an important modality and independent factor associated with improved survival in
patients undergoing esophagectomy for cancer.
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Introduction
Imaging is fundamental to improved cancer staging and large-
ly guides treatment decision-making. Radiological staging
investigations including computed tomography (CT) and pos-
itron emission tomography (PET) provide anatomical and
functional information and have greatly impacted clinical
practice [1–3].
Positron emission tomography integrated with computed
tomography (PET/CT) is now an established and evidence-
based part of the modern radiological staging algorithm of
esophageal cancer (EC) [4, 5]. Reported benefits include the
detection of distant metastases not detected by CT, which
changes management in up to 38% of patients [6].
Yet PET/CT is not without limitations. Endoscopic ultra-
sound (EUS) has been reported to be superior in staging both
the primary tumor and local lymph nodes [7], and no evidence
has yet emerged that use of PET/CT has been associated with
improved overall survival (OS) [8]. Moreover, important re-
configuration of UK esophagogastric cancer services has oc-
curred over the last decade, which has been accompanied by
better clinical outcomes. The National Oesophago-Gastric
Cancer Audit (NOGCA) has emphasized that better patient
selection by improved radiological and physiological staging
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accuracy, more use of neo-adjuvant chemotherapy, less post-
operative morbidity and mortality, and centralization of ser-
vices are all significant factors in improving survival after
potentially curative esophagectomy [9]. Determining the par-
ticular role PET/CT may have played in influencing outcome
after potentially curative esophageal cancer surgery is conse-
quently challenging, and likely not to undergo a randomized
control trial process.
Propensity score (PS) analysis facilitates measurement of
the probability of receiving a particular treatment modality
related to a number of variables, and represents a strong and
powerful alternative strategy to explore cause, compared with
orthodox statistical adjustment [10]. PS analysis adjusts for
potential confounders, balancing important co-variables such
as baseline characteristics or therapies, and is an alternative to
control trials where ethical or practical challenges prohibit
randomization, enhancing fair comparison [11, 12].
The aim of this study was to analyze the influence of 18-
FDG PET/CT introduction on OS after esophagectomy for
cancer when compared with historical controls by means of
PS analysis. The hypothesis was that PET/CT introduction
into the routine staging algorithm of patients diagnosed with
EC was associated with improved OS after potentially cura-
tive surgery. The setting was a UK Upper Gastrointestinal
(UGI) cancer network serving a population of 1.8 million.
Materials and methods
All patients diagnosed with EC of any cell type who
underwent surgery and had PET/CT imaging during the pre-
operative staging period in the South EastWales regional UGI
cancer network were studied prospectively between January
1, 2009 and August 31, 2016. These patients were compared
with a historical cohort of consecutive patients undergoing EC
surgery between January 1, 1998 and January 1, 2009, staged
with the network’s historical staging algorithm pre-PET/CT.
Exclusion criteria included patients undergoing PET/CT for
Siewert type III esophagogastric junctional cancer with prox-
imal esophageal extension, and patients undergoing salvage
esophagectomy following initial definitive chemoradiothera-
py (dCRT).
Patients proceeded to PET/CT staging only if they were
suitable for potentially curative treatment on the grounds of
CT stage and performance status, and was concurrently ar-
ranged with EUS examination. PET/CT was used for pre-
treatment staging only (Fig. 1) and was not used for restaging
after neoadjuvant therapy. All PET studies were integrated
PET/CT and no patients received PET imaging alone. Detail
of the networks’ EUS staging protocol has been described
previously [13]. Patients’ fitness was assessed by cardiopul-
monary exercise testing (CPX) [14], and the final manage-
ment plan was determined at the regional cancer network
multi-disciplinary team (MDT) meeting. All staging investi-
gations were reported in accordance with the UICC Tumour
Node Metastasis (TNM) staging methods [15]. The primary
outcome measure was OS from diagnosis. Secondary out-
come measures were proven recurrence patterns and disease-
free survival (DFS). Ethical approval, sought from the region-
al ethics committee, was waived because the study was
deemed to represent service evaluation. A number of devel-
opments in the management of EC occurred during the study
period, including changes in practice based upon the publica-
tion of randomized clinical trials, the introduction of an en-
hanced recovery program in 2008 [14] and finally, centraliza-
tion of the Upper Gastrointestinal (UGI) cancer regional net-
work service in South East Wales from August 1, 2010 [16].
PET/CT protocol
PET/CT examinations were performed at two centers. At the
first center (site 1), a total of 87 patients had PET/CT exami-
nations performed using a Philips 16 slice Gemini GXL ded-
icated PET/CT scanner (Philips Medical Systems, Cleveland,
OH, USA). The uptake time was 60 min. A standard admin-
istered activi ty of 350 MBq of FDG was given.
Reconstructions were performed using a 3D acquisition with
non-time of flight acquisition for 4 min per bed position.
Fig. 1 Fused PET/CT (above) and CT (below) images of soft tissue
metastases (white and black arrows) in a patient initially considered suit-
able for curative treatment. However, the management became palliative
once the metastases were detected
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Four hundred and eighty-five patients were imaged at
the second center (site 2) using a GE Discovery 690
PET/CT scanner (GE Healthcare, Pollards Wood,
Buckinghamshire, UK). Serum glucose levels were rou-
tinely checked and confirmed to be less than 7.0 mmol/l
prior to imaging. Patients received an activity of 4 MBq
of 18F-FDG per kilogram of body weight. Uptake time
was 90 min. PET images were acquired at 3 min per
field of view. The length of the axial field of view was
15.7 cm. Images were reconstructed with the ordered
subset expectation maximization algorithm, with 24 sub-
sets and two iterations. Matrix size was 256 × 256 pixels,
using the VUE Point ™ time of flight algorithm. CT
images were acquired in a helical acquisition with a pitch
of 0.98 and a tube rotation speed of 0.5 s. Tube output
was 120 kVp with output modulation between 20 and
200 mA. Matrix size for the CT acquisition was 512 ×
512 pixels with a 50-cm field of view. At both centers,
all patients were starved for a minimum of 6 h prior to
imaging and no oral or intravenous contrast was
administered.
The assignment of lymph nodes as involved or unin-
volved on PET images at the two centers was based on
subjective clinical assessment in each case. In general,
nodes were only assigned as involved if they showed
discernible tracer uptake above that of background and
were identified separately from the primary tumor. Other
factors affecting the classification of nodes were the mor-
phology, size, and relative uptake of the node in question
in comparison to the primary tumor. No specific SUV or
size cut off was used in assignment of nodes as benign
or malignant. Lymph nodes considered physiological or
related to an alternative etiology were excluded from the
N stage.
Treatment
Patients were selected for radical treatment (surgery or
dCRT) based on perceived radiologic stage, comorbidity,
and patient choice according to algorithms described pre-
viously [17–19]. The standard surgical approach consisted
of subtotal trans-thoracic esophagectomy (TTO) as de-
scribed by Lewis and Tanner. Trans-hiatal esophagectomy
(THO), as described by Orringer, was used selectively in
patients with adenocarcinoma of the lower third of the
esophagus with significant cardiorespiratory risk profiles,
or T1/2 N0 disease. All procedures used an open ap-
proach, and esophageal resection was defined as poten-
tially curative if all visible tumor was removed, and both
proximal and distal resection margins were free of tumor
on histological examination. R1 resection was defined as
positive longitudinal or circumferential margin status on
histological examination [20].
Follow-up evaluation
Patients were reviewed every 3 months for the first year, and 6
monthly thereafter until 5 years or death. Patients underwent
clinical assessment and venous blood sampling including
carcinoembryonic antigen (CEA) measurements. Patients
who were suspected to have disease recurrence based on clin-
ical assessment or a raised venous CEA underwent computed
tomography or endoscopy. Patterns of recurrence were de-
fined as loco-regional, distant (metastatic), or both loco-
regional and distant, when both were diagnosed concurrently.
The time of recurrence was taken as the date of the confirma-
tory investigation. The patient cohort was analyzed in January
2017. No patients were lost to follow-up and death certifica-
tion was obtained from the Office for National Statistics via
Cancer Network Information System Cymru (CaNISC).
Statistical methods
Grouped data were expressed as median (range) and non-
parametric methods used throughout. Propensity scores were
generated using appropriate logistic regression model, and
included all relevant independent variables thought to be po-
tential confounding factors and those which affect outcome.
Co-variate adjustment was performed using the propensity
scores, which were assessed for balance across groups using
a Student’s t test and defined by |d| > 0.25. The variables were
considered by the MDT and comprised age group, gender,
tumor histology, pathological T and N stage, operation type,
and site of PET/CT examination. The dependent variable was
whether the patient underwent PET/CT staging. The probabil-
ities option was chosen to generate propensity scores, which
were then used in a regression, covariate adjustment, to esti-
mate the effect of exposure of PET/CT on DFS and OS. DFS
was calculated by measuring the interval from a landmark
time of 6 months after diagnosis to the date of recurrence; an
approach mirroring previous randomized trials [21, 22] and
allowing for variance in time to definitive surgery. Events
resulting in a failure to complete curative treatment, such as
palliative surgery, operative mortality, and disease progression
during neoadjuvant therapy, were assumed to occur at this
landmark time, to facilitate intention-to-treat analysis. OS
was measured from the date of diagnosis, and cumulative
survival calculated according to the method of Kaplan and
Meier. Differences between groups were analyzed with the
log rank test. Univariable analyses examining factors
influencing survival were examined initially by the life table
method ofKaplan andMeier, and variables significant at the p
< 0·010 level were entered into a forward conditional Cox
proportional hazards model. All statistical analysis was per-
formed with SPSS® (IBM® SPSS® Statistics v23.0.0.0, IBM
Corporation, Armonk, NY, USA).
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Results
In total, 1167 patients were diagnosed with EC between 1998
and 2016 (Fig. 2). Of these, 595 were diagnosed between 1998
and 2009 (pre-PET cohort) and 572 were diagnosed between
2009 and 2016 (post-PET cohort). Of the 595 in the pre-PET
cohort, 322 (54.1%) did not proceed to resection because 180
(55.9%) had inoperable disease, 116 (36.0%) had pre-existing
comorbidity, and 26 (8.1%) because of patient choice.
Following the introduction of PET/CT (2009–2016), 572 pa-
tients were diagnosed with esophageal and junctional cancers
of which 223 (40.0%) underwent EC resection. Of the 349
(61.0%) patients that did not progress to surgical resection, 179
(51.3%) had inoperable disease and 138 (39.5%) had pre-
existing co-morbidity precluding curative treatment. Sixteen
(4.6%) had predominantly gastric cancer extending above the
esophagogastric junction (an exclusion criterion in this study),
and 16 (4.6%) underwent endoscopic mucosal resection (EMR).
Following propensity scoring, 496 consecutive patients
were eligible for inclusion, 273 pre-PET/CT, and 223 patients
post-PET/CT. Twenty-two (9.9%) patients had non-avid tu-
mors on PET/CT, but were included on an intention-to-treat
analysis basis. Propensity scores were generated for all 496
patients in the cohort. The propensity scores were balanced
across the two groups, Student’s t test p = 0.212 and there was
no covariate exhibiting a large imbalance (|d| > 0.25). Patient
demographics are detailed in Table 1.
The operative approach was trans-thoracic in 233 (47.0%),
trans-hiatal in 200 (40.3%), and a three-stage approach was used
in six (1.2%) patients. Open and close laparotomywas performed
in 57 (11.5%) patients either due to un-resectable tumor or meta-
static disease. Pathological examination revealed R1 resection
specimens (microscopic margin involvement) in 166 (33.5%) pa-
tients. Operative mortality occurred in 17 (3.4%) patients within
30 days of surgery. More trans-hiatal esophagectomies and three-
stage esophagogastrectomies were performed in the post-PET/CT
cohort than the pre-PET/CT cohort, which contained more trans-
thoracic esophagectomies (p< 0.0001). The post-PET/CT cohort
also underwent marginally more open and close laparotomies for
undetected distant metastases (n= 27, 12.1%) compared with the
pre-PET/CTcohort (n= 30, 11%, p= 0.698). Themedian follow-
up was 26 months (range, 6 to 220), with 476 patients (96.1%)
followed up for 1 year or until death, 447 (90.0%) for 2 years, 418
(84.3%) for 3 years, and 375 (81.4%) for 5 years.
Duration of survival
Disease-free survival
For patients with all pathological stages of disease, median DFS
was 16 months in the pre-PET/CT cohort, compared with
35 months in the post-PET/CT cohort (p = 0.049; Fig. 3). One-,
2-, and 3-year cumulative DFS in the pre-PET/CT cohort was
56.5, 41.4, and 34.4% respectively, compared with 61.9, 52.6,
and 49.3%, in the post-PET/CT cohort. Following PET/CT in-
troduction, median-, 1-, 2-, and 3-year DFS increased by
19 months, 5.4, 11.2, and 14.9%, respectively. All factors asso-
ciated with DFS on univariable analysis are shown in Table 2.
Fig. 2 CONSORT diagram
detailing the creation of both pre-
PET and post-PET cohorts
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Overall survival
For patientswith all pathological stages of disease,medianOSwas
28months in the pre-PET/CTcohort, comparedwith 50months in
the post-PET/CT cohort (p=0.004; Fig. 4). One-, 2-, and 3-year
cumulative OS in the pre-PET/CT cohort was 79.1, 55.7, and
42.5%, respectively, compared with 86.2, 68.8, and 57.8% in the
post-PET/CT cohort. Following PET/CT introduction, the medi-
an-, 1-, 2-, and 3-year OS increased by 22 months, 7.1, 13.1, and
15.3%, respectively. All factors associated with OS on univariable
analysis are shown in Table 3.
Table 1 Details of the patients before and after PET/CT introduction
Pre-PET/CT Post-PET/CT p value
Number (%) 273 (55.0) 223 (45.0)
Median age years (range) 61 (31–80) 64 (36–77) 0.036§
< 50 38 (13.9) 23 (10.3)
50–59 80 (29.3) 51 (22.9)
60–69 100 (36.6) 97 (43.5)
> 70 55 (20.2) 52 (23.3)
Gender 0.323†
Male 213 (78.0) 182 (81.6)
Female 60 (22.0) 41 (18.4)
Tumor type 0.011†
Adenocarcinoma 224 (82.1) 201 (90.1)
SCC 49 (17.9) 22 (9.9)
Oncological therapy
Neoadjuvant – all types 176 (66.4) 149 (66.8) 0.584†
Neoadjuvant chemoRx 126 (71.5) 109 (73.1) 0.493†
Neoadjuvant CRTx 50 (28.4) 40 (26.8) 0.914†
Surgery alone 97 (35.6) 74 (33.2) 0.584†
Operation type < 0.0001†
TTO 150 (54.9) 83 (37.2)
THO 93 (34.1) 107 (50.0)
3 Stage 0 (0) 6 (2.7)
Open and close 30 (11.0) 27 (12.1)
Pathological T stage 0.012†
HGD/CPR 16 (5.8) 17 (7.6)
T1 33 (12.1) 48 (21.5)
T2 31 (11.4) 24 (10.8)
T3 141 (51.6) 101 (45.3)
T4 22 (8.1) 6 (2.7)
Open and close 30 (11.0) 27 (12.1)
Pathological N stage 0.381†
N0 112 (41.0) 103 (46.2)
N1 67 (24.5) 48 (21.5)
N2 38 (13.9) 33 (14.8)
N3 26 (9.5) 12 (5.4)
Open and close 30 (11.0) 27 (12.1)
Pathological Stage (TNM 7) 0.069†
CPR 15 (5.0) 13 (5.8)
Stage I 48 (17.6) 56 (25.1)
Stage II 60 (22.0) 48 (19.7)
Stage III 20 (44.0) 75 (33.6)
Stage IV 0 (0) 2 (0.8)
R1 resection 83 (30.4) 83 (37.2) 0.198†
Operative mortality 11 (4.0) 6 (2.7) 0.415†
ACA adenocarcinoma, SCC squamous cell carcinoma, neoadjuvant
therapy –all types, chemotherapy/chemo radiotherapy; neoadjuvant
chemoRx, neoadjuvant chemotherapy, neoadjuvant CRTx, neoadjuvant
chemo radiotherapy, THO trans hiatal esophagectomy, TTO transthoracic
esophagectomy; 3 stage 3-stage esophagectomy; HGD/CPR high-grade
dysplasia/complete pathological response,R1 positive resectionmargin, §
Mann–Whitney U test; † Chi-squared test
Fig. 3 Cumulative disease-free survival related to introduction of PET/
CT
Table 2 Univariable analysis of factors associated with disease-free
survival
Chi2 df p value
Gender 0.446 1 0.504
Age 3.427 3 0.330
Tumor histology 0.164 1 0.686
PET/CT 3.964 1 0.046
PET/CT scanner 0.244 1 0.621
Neoadjuvant therapy (all types) 10.837 1 0.001
Neoadjuvant chemoRx 19.474 1 < 0.0001
Neoadjuvant CRTx 0.684 1 0.408
Surgery type* 2.620 2 0.270
pT stage 390.092 5 < 0.0001
pN stage 418.258 4 < 0.0001
R1 resection 365.946 2 < 0.0001
df degrees of freedom, Age < 50, 50–59, 60–79, > 70, PET/CT location,
Cheltenham/Cardiff, Neoadjuvant therapy –all types, chemotherapy/
chemo radiotherapy, Neoadjuvant chemoRx neoadjuvant chemotherapy,
Neoadjuvant CRTx, neoadjuvant chemo radiotherapy, Surgery type
*Trans hiatal esophagectomy/trans thoracic esophagectomy/3-stage
esophagectomy, pT pathological T stage, pN pathological N stage, R1
positive resection margin
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Multivariable analysis
The factors found to be significantly associated with DFS and
OS on univariable analysis were entered into a multivariable
analysis using Cox’s proportional hazards model, the results
of which are shown in Table 4. The number of events per
variable was 38.14.
Recurrence rates
Table 5 illustrates the recurrence patterns within the two co-
horts. The overall number of patients diagnosed with cancer
recurrence was 199 (45.3%).
Recurrent cancer was observed in 125 patients (51.4%) in
the pre-PET/CTcohort, compared with 74 patients in the post-
PET/CT cohort (37.8%, Chi2 8.199; df 1, p = 0.004). The site
of recurrent cancer was less likely to be distant in location after
PET/CT introduction (39.5 vs. 27.0%, p = 0.006).
Discussion
This is the first study and propensity score analysis to demon-
strate a positive significant correlation between the introduc-
tion of PET/CT into an EC staging algorithm and a reduction
in cancer recurrence, with a commensurate increase in dura-
tions of survival, irrespective of stage, in patients undergoing
potentially curative surgery.
In keeping with previous reports [5, 6], PET/CT upstaged
78 patients (13.2%), changing their treatment modality and
precluding surgery. Median-, 1-, and 3-year OS increased sig-
nificantly by 22 months, 13.1 and 15.3%, respectively after
introduction of PET/CT. Cancer recurrence was 13.6% less
common after PET/CT introduction, with fewer loco-
regional and distant recurrence events when compared with
historical controls. Consequently, the hypothesis addressed,
namely that introduction of PET/CT into the routine EC stag-
ing algorithm was associated with improved OS after poten-
tially curative surgery, was proven correct.
Reports regarding the influence of PET/CTwithin EC stag-
ing algorithms on patient long-term outcomes related to
Fig. 4 Cumulative overall survival related to introduction of PET/CT
Table 3 Univariable analysis of factors associated with overall survival
Chi2 df p value
Gender 0.246 1 0.620
Age 4.609 3 0.203
Tumor histology 0.032 1 0.859
PET/CT 8.388 1 0.004
PET/CT scanner 0.306 2 0.580
Neoadjuvant therapy (all types) 10.837 1 0.001
Neoadjuvant chemoRx 17.388 1 < 0.0001
Neoadjuvant CRTx 1.028 1 0.311
Surgery type* 4.356 2 0.113
pT stage 160.877 5 < 0.0001
pN stage 177.154 4 < 0.0001
R1 136.000 2 < 0.0001
df degrees of freedom, Age < 50, 50–59, 60–79, > 70, PET/CT location,
Cheltenham/Cardiff, Neoadjuvant therapy –all types, chemotherapy/
chemo radiotherapy, Neoadjuvant chemoRx neoadjuvant chemotherapy,
Neoadjuvant CRTx, neoadjuvant chemo radiotherapy, Surgery type
*Trans hiatal esophagectomy/trans thoracic esophagectomy/3-stage
esophagectomy, pT pathological T stage, pN pathological N stage, R1
positive resection margin
Table 4 Multivariable analysis of factors associated with disease-free
and overall survival
Variable HR 95% CI p value
Disease-free survival
pT stage 1.526 1.31–1.78 < 0.0001
pN stage 1.371 1.26–1.49 < 0.0001
Overall survival
PET/CT introduction 0.688 0.53–0.89 0.004
pT stage 1.496 1.28–1.75 < 0.0001
pN stage 1.114 1.04–1.19 0.001
pT pathological T stage, pN pathological N stage
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recurrence and durations of survival are few. Torrance et al.
[8], from Cheltenham, England, reported in a retrospective
review of 200 EC patients undergoing PET/CT, 128 of who
underwent esophageal resection. Although PET/CT altered
treatment intent in 19 patients (9.5%), no significant differ-
ence was noted in post-operative mortality, or early recurrence
where PET/CTwas performed when adjusted for age, gender,
stage, or neoadjuvant chemotherapy (odds ratio 1.136, p =
0.761). Moreover, PET/CT had no significant effect on sur-
vival (Chi2 0.710, p = 0.400). The difference in survival pre-
and post-PET/CTwas approximately 2, 6, and 7% at 1, 2, and
3 years, compared with 7.1, 13.1, and 15.3% in this study.
Torrance et al. concluded that PET/CT improved the accuracy
of EC staging, avoiding potentially unnecessary surgery, and
contended that missed occult metastases did not appear to be
the primary cause of early EC recurrence.
The current study has potential inherent limitations. The
PET/CT examinations were performed at two centers, using
different scanners, protocols, and uptake times, with patients
in the early part of the study referred to site 1 (Philips 16 slice
Gemini GXL), prior to the opening of site 2’s PET/CT in
2010. The main differences between the two centers were
firstly, a 60-min uptake time on the first scanner (site 1), and
a 90-min uptake time in site 2. Longer uptake times lead to
higher tumor-to-background tracer uptake and may therefore
increase conspicuity of nodal and distant metastases [23].
Secondly, the site 2 scanner had time of flight correction
whereas the site 1 scanner did not. Time-of-flight reconstruc-
tions improve signal-to-noise ratio and improve lesion conspi-
cuity [24]. Thirdly, at the site 1 center, images were acquired
for 4 min per bed position, whereas at site 2, the acquisition
was 3 min per bed position. This would be expected to lead to
some improvement of image quality at the site 1 center, pro-
vided that the patient was able to remain motionless through-
out the longer acquisition, which might mitigate the other
factors. The potential heterogeneity introduced within the
PET/CT imaged group was a reason why the location of the
PET/CT scan was a covariate within the propensity score and
as a result, adds great strength to this study.
The study included patients treated over a 17-year period
with a variety of treatment strategies. Evolution in UGI cancer
practice would have naturally occurred during the time frame
of this study, including neoadjuvant therapy regimen modifi-
cations, more detailed patient risk profile assessment related to
patients’ fitness for surgery including objective assessment of
physical fitness with cardiopulmonary exercise testing, cen-
tralization of surgical services, and the introduction of an
Enhanced Recovery Program, all of which might represent
potential confounding factors.
Conversely, the strengths of the study are that the data was
collected prospectively, from a well-defined geographical area
served by an established regional UGI cancer network andmul-
tidisciplinary team. This team included six experienced special-
ist surgeons, with a referring population base of 1.8 million,
accepting over 500 cases per year, generating in excess of 100
potentially curative esophagogastric resections, whose outcome
data is well audited and of public record [25]. The survival and
prognostic data are especially robust because no patients were
lost to follow-up and causes and dates of death were obtained
from death certificates provided by the Office for National
Statistics. Moreover, the improvement in survival cannot be
explained by poor outcomes in the historical control cohort,
which compare favorably with the clinical outcomes data pub-
lished in the most recent NOGCA report [26]. NOGCA cumu-
lative survival at 1, 2, and 3 years was approximately 70, 50,
and 40% compared with 79.1, 55.7, and 42.5% in propensity
matched historical controls. Furthermore, NOGCA reported
30-day mortality of 4.5%, between 2007 and 2009, comparable
with the 4% observed in the propensity matched historical co-
hort of this study.
Table 5 Recurrence rates related
to cohort for patients who
received curative surgery
Pre-PET/
CT
Post-PET/
CT
Total p value
Number of patients* 243 196 439
Recurrence 125 (51.4) 74 (37.8) 199 0.004
Site of recurrence
Locoregional 55 (22.6) 34 (17.3) 89 0.171
Distant 96 (39.5) 53 (27.0) 149 0.006
Time to recurrence (months)
Overall 15 (2–85) 10 (2–93) 0.308
Locoregional 15 (2–85) 14.5 (4–93) 0.392
Distant 14 (2–72) 10 (2–69) 0.7
Open and close laparotomy 30 27 57
Figures are numbers of patients with percentages in parentheses; Site of recurrence, inclusive of patients diagnoses
with both locoregional and distant disease at time of diagnosis;
*Excluding open and close procedures
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Multivariable model analyses have been considered the
orthodox and preferred statistical way of assessing the effect
of possible predictors on outcomes after controlling for base-
line characteristics, yet their suitability depends on consistent
assumptions underlying any given model. Regression analy-
ses of DFS and OS by means of propensity scores overcome
some potential biases, and although it is considered the most
useful statistical method for controlling confounders, provid-
ing appropriate estimates even when faced with extreme cor-
relation between confounders and the exposure [27], it cannot
account for unknown confounders [28]. Propensity score anal-
ysis is well suited when several risk-adjusted outcomes are
under assessment (DFS and OS), because such scoring sim-
plifies multiple outcome weighting, which once calculated
can be related to each specific outcome measure.
In conclusion, this propensity score regression analysis
further supports the use of PET/CT in EC staging pathways,
and in the absence of an adequately powered randomized
controlled trial, provides the best level of research evidence
regarding the influence of PET/CT on outcome after poten-
tially curative esophagectomy for cancer. Risk profile as-
sessment represents an important development in the selec-
tion algorithm for patients diagnosed with invasive EC.
While this is often assumed to relate to patients’ physical
fitness, clearly avoiding hopeless radical, and unnecessary
surgery, in patients with undetected occult metastases is an
important allied strategy, if EC treatment outcomes are to be
optimized. The findings of this study have shown that the
introduction of PET/CT into the global patient assessment
process changed the risk profile of over one in ten patients,
reduced global recurrence by one-quarter, and improved
median survival by a full year. A health economic analysis
of the cost-effectiveness of PET/CT is now desirable to es-
timate the potential allied clinical and fiscal benefits avail-
able to upper gastrointestinal cancer networks.
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